Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048557
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38818978
3.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528035
4.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638723
5.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608183
6.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774221
7.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Cancer
; 125(5): 750-760, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561775
8.
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Eur J Nucl Med Mol Imaging
; 45(5): 712-719, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29270787
9.
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.
Haematologica
; 102(4): 773-784, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057743
10.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Ann Hematol
; 96(12): 2071-2078, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29063955
11.
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Haematologica
; 101(3): 363-70, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659916
12.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107338
13.
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Eur J Nucl Med Mol Imaging
; 43(3): 414-21, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26475305
14.
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
Expert Rev Hematol
; : 1-16, 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38770902
15.
Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020.
Front Oncol
; 13: 1182971, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37534259
16.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine
; 60: 102017, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396807
17.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol
; 12: 890376, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924160
18.
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 39(2): 116-125, 2021 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33151787
19.
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.
Clin Lymphoma Myeloma Leuk
; 20(10): e629-e644, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32605897
20.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol
; 7(6): e456-e468, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359506